Potential treatment strategy of risperidone in long-acting injectable form for schizophrenia with dopamine supersensitivity psychosis

Schizophrenia Research

Volumn 145, Issue 1-3, 2013, Pages 130-131

  Kimura, Hiroshi ^a   Kanahara, Nobuhisa ^a   Watanabe, Hiroyuki ^a   Iyo, Masaomi ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOCAPRAMINE; HALOPERIDOL; LEVOMEPROMAZINE; OLANZAPINE; RISPERIDONE;

ADULT; AUDITORY HALLUCINATION; CASE REPORT; CLINICAL FEATURE; CONVALESCENCE; DISEASE EXACERBATION; DOPAMINE SUPERSENSITIVITY PSYCHOSIS; DOSE RESPONSE; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG TOLERANCE; DRUG TREATMENT FAILURE; FUNCTIONAL STATUS; HUMAN; LETTER; MALE; MENTAL STRESS; PERSECUTORY DELUSION; PRIORITY JOURNAL; REMISSION; RESTLESSNESS; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADULT; DOPAMINE AGENTS; HUMANS; LONGITUDINAL STUDIES; MALE; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA;

EID: 84875274490     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.01.008     Document Type: Letter

References (10)

1. Chouinard G. Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophr. Res. 1990, 5:21-33.
2. Chouinard G., Chouinard V.A. Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother. Psychosom. 2008, 77(2):69-77.
3. Chouinard G., Margolese H.C. Manual for the extrapyramidal symptom rating scale (ESRS). Schizophr. Res. 2005, 76:247-265.
4. Eerdenkens M., Hove I.V., Remmerie B., Mannaert M. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr. Res. 2004, 70:91-100.
5. Fallon P., Dursun S.M. A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis. J. Psychopharmacol. 2011, 25(6):755-762.
6. Iyo M., Tadokoro S., Kanahara N., Hashimoto T., Niitsu T., Watanabe H., Hashimoto K. Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. J. Psychopharmacol. 2012, (Epub ahead of print).
7. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45:789-796.
8. Kane J.M., Eerdenkens M., Lindenmayer J.P., Keith S.J., Lesem M., Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am. J. Psychiatry 2003, 160:1125-1132.
9. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol. Rep. 1962, 10:799-812.
10. Tadokoro S., Okamura N., Sekine Y., Kanahara N., Hashimoto K., Iyo M. Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis. Schizophr. Bull. 2012, 38(5):1012-1020.